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toxicology
Craig A Poland1*, Mark R Miller2, Rodger Duffin3 and Flemming Cassee4,5The issue of reproducibility of results in toxicology
has long been a concern and, perhaps, at the back of
many of our minds but not necessarily at the fore-
front of our thinking – ‘the elephant in the room’.
Are the results we have published literally our results
or are they reproducible and truly part of a credible
theory? In the excellent editorial by Gary Miller [1],
Editor-in-Chief of the journal Toxicological Sciences, he
discusses the issue of reproducibility in scientific manu-
scripts; an important topic and one that has received in-
creasing attention of late from researchers, journals and
funding bodies.The problem?
The editorial on the topic of reproducibility, or lack of,
in toxicology follows on from concerns raised in the
journal Nature [2,3], including a collation of publications
and comments on the journals website (http://www.na-
ture.com/nature/focus/reproducibility/). In addition in
January this year, the Director and Deputy Director of
National Institute of Health (NIH) outlined what the
NIH plans to do to tackle the problem [4]. Of greatest
concern, is the contribution poor reproducibility can
have on the attrition rates of potential therapies as they
move from preclinical testing (in situ, in vitro and in vivo)
to rigorous clinical trials. Clinical trials require specific
levels of stringency (e.g. power estimates, blinding, ran-
domisation, etc. [4]) that are not always observed within
basic research. Whilst the issue of attrition, or the failure
of novel therapies to reach their full potential, pertains to
a sub-set of scientific endeavour, the issue of irreproduc-
ibility impacts on all areas of science. This can range from
public (mis)trust of science to the unintentional squan-
dering of increasingly limited time and funds pursuing
blind avenues. The implications of this should not be
underestimated. Research agendas, whilst ultimately* Correspondence: craig.poland@iom-world.org
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bodies, public opinion and political motivations. All will
play a role in the distribution of a limited pool of research
funds, and rightly expect progress in return for financial
support. Yet a lack of reproducibility can destabilise re-
search and undermine the confidence of stakeholders. An
additional area of concern relating to reproducibility is
when findings are translated into the ‘real world’ where
acceptance and use of premature conclusions resulting
from uncertain data [5] can have profound implications.
This may be in the form of turning the tide of trust
towards or against new technologies (if unfounded) or
where regulatory decisions are made based on shaky foun-
dations. As stated by Gio Batta Gori, Editor-in-Chief of
the Journal Regulatory Toxicology and Pharmacolgy [5],
this is not just a scientific issue but also an ethical one;
how uncertain results are presented to, interpreted and
consumed by non-academic organisations.The cause?
As with the Editorials cited above [1-4], it is important
to clearly state that this is not a question of scientific
misconduct, but instead often one of an increasing num-
ber of simple mistakes in the research design. These
may occur everywhere from poorly designed protocols,
incorrect controls, underpowered studies, improper data
analysis/reporting (such as the use of error bars or confi-
dence intervals [6]), the differentiation between technical
replicates and independent experiments [7,8], as well as
inaccurate/incomplete reporting of methods [7]. This
latter issue has been suggested to be especially crucial,
as even minor modifications of conventional in vitro
toxicity assays (e.g. due to sample handling/ preparation
issues) can have an important impact on study reprodu-
cibility [9].
These and many more factors harm the reproducibility
of studies. However, the articles on reproducibility cited
above do not advocate a ‘thou shalt’ approach, which is
something we at Particle and Fibre Toxicology agree
with. Instead these articles wish to offer reasons as toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ways to improve reproducibility that could be useful to
us all. The articles point out that it is not just the indi-
vidual researcher or senior investigators that are at fault,
but also that motivations in sciences are too heavily in-
fluenced by a ‘rewards system’ whereby large scale, high
volume, low cost studies are incentivised, and continued
publication in high-profile journals is, more-than-ever, a
necessity – “publish or perish”. These factors can im-
prove scientific progress, pushing up standards and out-
put/ pushing down costs, however there is a clear risk
that the intensity and speed of this competitive approach
could come at the cost of scientific rigour.
One commenter on the 2012 Nature editorial [2] of-
fered that “one could say there is no way to have real
science and money hand in hand especially when one is
required to generate money with the respective science”.
Many will recognise the truth in such a statement,
although others would argue that this is the environ-
ment we inhabit and one that is increasingly unlikely to
change. Today’s research environment is increasingly
based on short-term contracts whereby acquisition of re-
search grants and publications are the main two drivers
(certainly from an Academic perspective) that offer the
foundations towards job stability. The competitiveness
of such a research environment will not promote more
expensive, longer-term projects that may be narrower in
terms of focus yet have the sufficient depth to provide
more rigorous and reproducible findings. To achieve
truly informative and reliable science, a balance has to
be struck between sufficiency, thoroughness and value for
money which is not necessarily something that can be
rushed.
Science is seen as ‘self-correcting’ due to the premise
that it is built on the replication of earlier work [4]. Yet
for this function to occur there is a requirement to valid-
ate key data, prior to its use as a foundation to advance
the research question. However, there is limited incen-
tive from journals and funding bodies to pursue such
studies, or to publish results that may contradict or con-
firm previous papers [3]. This is often a vital service to
avoid wasting money and effort, and provide confidence
in future scientific output. However, some top-tier jour-
nals are beginning to recognise the importance of this
aspect of research by providing journal space for this
type of study, particularly where they confirm or refute
important and/or controversial findings [3]. The useful-
ness of negative findings or contradictory data should
also be adopted more widely in peer-reviewed journals
[10]. We acknowledge that Particle and Fibre Toxicology
also uses novelty often as a key selection criterion, as it
should do. However, reviewers are encouraged to give
investigators a fair chance when submitting replication
studies, if clearly warranted and properly substantiated.The solution?
How do we address this apparent conflict? Collins and
Tabak of the National Institutes of Health (NIH) point
to community responsibility and propose a range of
approaches to tackle the various levels in the hierarchy
of scientific research that may have contributed to the
increasing concern in this area [4]. Their advice ranges
from journals being encouraged to devote more space to
research conducted in an exemplary manner, as well
as those that report negative findings [10]. They also
highlight that Nature Publishing Group have abolished
restrictions on the length of Methods sections to ensure
the reporting of essential experimental detail [3]. They
also suggest a move away from using “arbitrary surro-
gates” of an investigator’s scientific contribution and fu-
ture potential when considering job promotion or grant
awards. In particular they emphasise that the use of rela-
tively uninformative measures such as the numbers of
grants awarded or numbers of publications in journals
with high impact factors may underestimate the true
value of a researcher’s output that could be low in num-
ber, but high in impact in a broader sense. Interestingly
the NIH is also considering strategies that provide
greater stability for investigators (at crucial career stages)
by offering more flexibility and longer project durations
within grant mechanisms to reduce the (perceived?)
pressure to generate positive results and numerous pa-
pers within short periods of time. This is an interesting
approach but also one that would need further support
from academic departments through a greater focus on
career development and a broader means of evaluating
what an individual brings to their department.
Whilst the approaches put forward by Collins and
Tabak are largely from a top-down perspective, the edi-
torial by Gary Miller [1] discusses a more fundamental,
ground-up approach for improving the rigour of day-to-
day scientific research. He suggests further encourage-
ment of researcher awareness of unintended bias by, as
Miller puts it, evoking the spirit of Karl Popper and
attempting to disprove what we believe to be true [1]. In
particular, to evoke a mind-set that reduces confirmation
bias where an experimenter (purposely, or inadvertently)
directs the course of study to confirm what they believe
to be true. Miller suggests that we too often attempt to
rid our experiments of any sort of experimental varia-
bility through good intention, but this in itself limits
reproducibility. Should we instead ‘add in a little vari-
ability’, i.e. ensure reproducibility of findings are main-
tained despite variables such as differences between lots
of reagents, different experimenters and laboratories per-
forming the test, etc? However the presence of varia-
bility is already well entrenched in biological sciences
where the complexity, instability and unpredictability
of biological systems is arguably more profound than
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chemistry and physics [5]. This is encapsulated within
‘Harvard’s law’ (and perhaps even taped-up as a notice
in your own cell culture laboratories) which states that
“Under the most rigorously controlled conditions of
pressure, temperature, volume, humidity, and other vari-
ables the organism will do as it damn well pleases”. The
field of particle and fibre toxicology, and especially
nanotoxicology, adds an additional layer of complexity
through the addition of surprisingly dynamic physi-
cochemical properties of particles, dispersion states, etc.
once such particles are employed in the biological model
of interest. Many particle/nano- journals now require
very high standards of independent characterisation of
the test compounds and reporting of methods, pro-
perties and sources of materials as standard; not just a
reliance of citation of other publications with similar
methodology. In a sense, one should characterize mate-
rials in such a way that the hypothesis of the study can
be addressed and that peers will be able to reproduce
the exposures.
The crux of this is the use of replication and rigorous
confirmation of an observed endpoint and this takes
time, funds and, in the case of in vivo studies, may also
be considered as non-ethical. Stakeholders (e.g. funding
bodies) have a responsibility to ensure that high-output
strategies do not represent a false economy due to a lack
of reproducibility. However the onus clearly lies on the
researchers also; what is required to prove, with con-
fidence, your results? For example, does significance at
n = 3–4 truly provide conclusive proof of a hypothesis?
Recently Johnson [1,11] suggested that the current
standard of p < 0.05 for statistical significance is a major
source of irreproducibility in both big and small data
sets alike. Aiming for a more stringent threshold level of
significance (such as 0.01 or 0.005) and greater use of
dose-response curves rather than single dose studies
would undoubtedly require more replicates. However,
it would also push researchers not to simply do ‘just
enough’ to demonstrate a positive finding, but to ensure
that the biological significance of findings are better rep-
resented across the spectrum of biological variability. At
very least, our conclusions and the adoption of bold
statements should be reflective of the statistical evi-
dence; where results are barely significant, it may be
more prudent to suggest that the results are indicative of
something rather than that they confidently state fact.
Understandably, many scientists will be less inclined
to risk undermining their prospects of grant funding and
career progression by increasing their proposal costs and
reducing publication rates. However, there are bottom-
up approaches that can be taken. These range from a
more conscientious approach to experimental design,
analysis and reporting (including training junior staff tobe similarly dedicated) to testing our hypotheses in
scientific forums, be that through on-line media or by
formal peer review. This editorial does not propose to
offer all of the solutions but simply add voice to the
growing concern and call for a collective response to the
issue and stimulate debate on the topic in all forums be-
cause as stated by Gary Miller “Toxicology just is not
toxicology without reproducibility” [1] and we whole
heartedly agree. There is no panacea but allow us to
offer five practical points to consider during study design
through to reporting the findings, from the perspective
of particle toxicology.
1. Be specific. For example, what is your sample?
If it’s graphene, then is it actually graphene i.e. a
monolayer, or is it few layer graphene, or graphite
platelets? If they are ambient particles, where and
how were they collected (date, time, weather
conditions etc.)? State this, it is important - later
studies may not replicate your results simply due to
inadvertently testing the non-similar materials i.e.
comparing apples and oranges.
2. Characterise, characterise, characterise. Only
with independent characterisation do you truly
know what you are testing and allow others to
reproduce your findings. Particle characteristics will
undoubtedly be a key driver of bioactivity.
Characterise in relation to your hypothesis or
research question - do not characterise because
there is a default list of parameters that you need
to check.
3. Use statistics to question your results rather
than simply confirming a theory. Ask yourself, is
barely statistically significant really biologically
relevant? Can you support/validate an entire
hypothesis or more controversially, a provocative
statement using P < 0.05?
4. Write your hypothesis in advance of running the
experiment. It should be clear from the
experimental design how you have tried to disprove
this. If your theory is robust it should survive your
best efforts to challenge it.
5. Take a ‘belts and braces’ approach to confirming
findings. Use multiple approaches, doses, time
points, replicates and controls. You don’t want to be
caught with your trousers down.Competing interests
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